Overview of Dr. Friedman
Dr. Claire Friedman is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from Yale School of Medicine and has been in practice 9 years. She is one of 497 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She has more than 50 publications and over 500 citings.
Office
160 East 53rd Street
New York, NY 10022
Education & Training
University of Pennsylvania Health SystemResidency, Internal Medicine, 2011 - 2014
Yale School of MedicineClass of 2008
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 2014 - 2025
PA State Medical License 2011 - 2014- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Clinical Trials
- A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer Start of enrollment: 2017 Aug 04
- A Study of SGN-STNV in Advanced Solid Tumors Start of enrollment: 2021 Jan 18
Roles: Principal Investigator, Contact
- A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Start of enrollment: 2023 Oct 18
Roles: Contact
Publications & Presentations
PubMed
- The Intrauterine Device: How to Deploy This Strategy in the Molecular World?Paul Johannet, Claire F Friedman
Clinical Cancer Research. 2024-11-15 - 1 citationsBasket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, ...Sarah Andres, Lindsey Finch, Alexia Iasonos, Qin Zhou, Jeffrey Girshman
Gynecologic Oncology. 2024-10-01 - Prognosis of isolated tumor cells and use of molecular classification in early stage endometrioid endometrial cancer.Eric Rios-Doria, Nadeem R Abu-Rustum, Kaled M Alektiar, Vicky Makker, Ying L Liu
International Journal of Gynecological Cancer. 2024-09-02
Press Mentions
MSK Research Highlights, June 25, 2024June 25th, 2024- Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022September 11th, 2022
- The Power of Shared Purpose: Transforming Gynecologic Cancer CareMarch 26th, 2024
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
